# Seven Fleet Capital Management LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2092021. Source: https://holderbook.com/funds/2092021-seven-fleet-capital-management-lp/

- Reported value: $605.9M
- Positions: 96
- Weight of the ten largest: 65.1%
- Filed: 2026-08-17

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| CG ONCOLOGY INC | [CGON](https://holderbook.com/stocks/CGON/) | $134.0M | 1,886,236 | 22.1% | 3 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $95.7M | 3,228,144 | 15.8% | 3 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $45.3M | 242,029 | 7.5% | 3 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $26.8M | 774,501 | 4.4% | 3 |
| LIQUIDIA CORPORATION | [LQDA](https://holderbook.com/stocks/LQDA/) | $20.5M | 256,603 | 3.4% | 3 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $18.5M | 365,386 | 3.1% | 3 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $14.8M | 111,334 | 2.4% | 3 |
| AVALO THERAPEUTICS INC | [AVTX](https://holderbook.com/stocks/AVTX/) | $14.2M | 770,765 | 2.4% | 3 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $12.9M | 110,393 | 2.1% | 1 |
| ASSEMBLY BIOSCIENCES INC | [ASMB](https://holderbook.com/stocks/ASMB/) | $11.9M | 433,147 | 2.0% | 3 |
| CENTURY THERAPEUTICS INC | [IPSC](https://holderbook.com/stocks/IPSC/) | $10.7M | 4,347,826 | 1.8% | 2 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $10.1M | 118,240 | 1.7% | 3 |
| TAYSHA GENE THERAPIES INC | [TSHA](https://holderbook.com/stocks/TSHA/) | $9.9M | 1,504,400 | 1.6% | 3 |
| VERADERMICS INC | [MANE](https://holderbook.com/stocks/MANE/) | $9.8M | 80,000 | 1.6% | 1 |
| ARRIVENT BIOPHARMA INC | [AVBP](https://holderbook.com/stocks/AVBP/) | $8.6M | 246,606 | 1.4% | 2 |
| TARSUS PHARMACEUTICALS INC | [TARS](https://holderbook.com/stocks/TARS/) | $7.9M | 117,067 | 1.3% | 3 |
| XENCOR INC | [XNCR](https://holderbook.com/stocks/XNCR/) | $7.8M | 368,305 | 1.3% | 3 |
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $7.8M | 220,126 | 1.3% | 2 |
| DAMORA THERAPEUTICS INC | [DMRA](https://holderbook.com/stocks/DMRA/) | $7.4M | 284,430 | 1.2% | 2 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $7.1M | 28,826 | 1.2% | 3 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $7.0M | 148,647 | 1.2% | 2 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $6.3M | 64,723 | 1.0% | 3 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $5.7M | 147,510 | 0.9% | 3 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $5.6M | 308,007 | 0.9% | 2 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $5.6M | 45,400 | 0.9% | 3 |
| MINERVA NEUROSCIENCES INC | [NERV](https://holderbook.com/stocks/NERV/) | $5.6M | 1,001,373 | 0.9% | 2 |
| EDITAS MEDICINE INC | [EDIT](https://holderbook.com/stocks/EDIT/) | $4.3M | 1,330,500 | 0.7% | 1 |
| CYTOMX THERAPEUTICS INC | [CTMX](https://holderbook.com/stocks/CTMX/) | $4.1M | 1,085,398 | 0.7% | 3 |
| EUPRAXIA PHARMACEUTICALS INC | [EPRX](https://holderbook.com/stocks/EPRX/) | $4.0M | 610,785 | 0.7% | 2 |
| SUTRO BIOPHARMA INC | [STRO](https://holderbook.com/stocks/STRO/) | $3.8M | 159,118 | 0.6% | 1 |
| RELAY THERAPEUTICS INC | [RLAY](https://holderbook.com/stocks/RLAY/) | $3.3M | 178,222 | 0.6% | 3 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $3.2M | 86,664 | 0.5% | 2 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $3.2M | 11,869 | 0.5% | 1 |
| SAGIMET BIOSCIENCES INC | [SGMT](https://holderbook.com/stocks/SGMT/) | $3.1M | 403,545 | 0.5% | 1 |
| ZAI LAB LTD | [ZLAB](https://holderbook.com/stocks/ZLAB/) | $2.9M | 136,016 | 0.5% | 2 |
| SAB BIOTHERAPEUTICS INC | [SABS](https://holderbook.com/stocks/SABS/) | $2.9M | 736,077 | 0.5% | 2 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $2.7M | 4,973 | 0.4% | 3 |
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $2.5M | 7,540 | 0.4% | 1 |
| RELMADA THERAPEUTICS INC | [RLMD](https://holderbook.com/stocks/RLMD/) | $2.4M | 348,265 | 0.4% | 1 |
| AGIOS PHARMACEUTICALS INC | [AGIO](https://holderbook.com/stocks/AGIO/) | $2.1M | 56,900 | 0.3% | 3 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $2.1M | 33,300 | 0.3% | 1 |
| SAVARA INC | [SVRA](https://holderbook.com/stocks/SVRA/) | $1.9M | 309,103 | 0.3% | 3 |
| C4 THERAPEUTICS INC | [CCCC](https://holderbook.com/stocks/CCCC/) | $1.8M | 381,169 | 0.3% | 2 |
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $1.8M | 29,800 | 0.3% | 3 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $1.7M | 16,252 | 0.3% | 3 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $1.6M | 77,930 | 0.3% | 1 |
| ZENTALIS PHARMACEUTICALS INC | [ZNTL](https://holderbook.com/stocks/ZNTL/) | $1.5M | 317,600 | 0.2% | 2 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $1.4M | 26,800 | 0.2% | 2 |
| LEONABIO INC | [LONA](https://holderbook.com/stocks/LONA/) | $1.4M | 154,153 | 0.2% | 3 |
| IDEAYA BIOSCIENCES INC | [IDYA](https://holderbook.com/stocks/IDYA/) | $1.4M | 37,865 | 0.2% | 2 |
| GERON CORP | [GERN](https://holderbook.com/stocks/GERN/) | $1.4M | 1,057,228 | 0.2% | 3 |
| ADLAI NORTYE LTD | [ANL](https://holderbook.com/stocks/ANL/) | $1.3M | 113,207 | 0.2% | 1 |
| CORVUS PHARMACEUTICALS INC | [CRVS](https://holderbook.com/stocks/CRVS/) | $1.2M | 82,890 | 0.2% | 2 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $1.2M | 23,285 | 0.2% | 2 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $1.2M | 13,300 | 0.2% | 2 |
| PERSPECTIVE THERAPEUTICS INC | [CATX](https://holderbook.com/stocks/CATX/) | $1.1M | 332,613 | 0.2% | 2 |
| ONKURE THERAPEUTICS INC | [OKUR](https://holderbook.com/stocks/OKUR/) | $1.1M | 240,963 | 0.2% | 1 |
| SUMMIT THERAPEUTICS INC | [SMMT](https://holderbook.com/stocks/SMMT/) | $1.1M | 73,300 | 0.2% | 1 |
| AN2 THERAPEUTICS INC | [ANTX](https://holderbook.com/stocks/ANTX/) | $1.0M | 208,946 | 0.2% | 2 |
| CONTINEUM THERAPEUTICS INC | [CTNM](https://holderbook.com/stocks/CTNM/) | $992.3K | 60,541 | 0.2% | 2 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $833.4K | 45,598 | 0.1% | 3 |
| VOYAGER THERAPEUTICS INC | [VYGR](https://holderbook.com/stocks/VYGR/) | $771.9K | 230,406 | 0.1% | 2 |
| INVENTIVA SA | [IVA](https://holderbook.com/stocks/IVA/) | $756.5K | 200,141 | 0.1% | 2 |
| Engene Therapeutics Inc | [ENGN](https://holderbook.com/stocks/ENGN/) | $711.1K | 411,065 | 0.1% | 1 |
| LARIMAR THERAPEUTICS INC | [LRMR](https://holderbook.com/stocks/LRMR/) | $704.3K | 230,921 | 0.1% | 2 |
| INHIBIKASE THERAPEUTICS INC | [IKT](https://holderbook.com/stocks/IKT/) | $704.2K | 346,900 | 0.1% | 3 |
| NEUROGENE INC | [NGNE](https://holderbook.com/stocks/NGNE/) | $693.8K | 22,060 | 0.1% | 1 |
| ISHARES TR | [IHI](https://holderbook.com/stocks/IHI/) | $681.9K | 13,800 | 0.1% | 1 |
| SILENCE THERAPEUTICS PLC | [SLN](https://holderbook.com/stocks/SLN/) | $660.0K | 60,107 | 0.1% | 3 |
| KRYSTAL BIOTECH INC | [KRYS](https://holderbook.com/stocks/KRYS/) | $659.3K | 1,774 | 0.1% | 3 |
| OPUS GENETICS INC | [IRD](https://holderbook.com/stocks/IRD/) | $588.3K | 143,137 | 0.1% | 2 |
| PALISADE BIO INC | [PALI](https://holderbook.com/stocks/PALI/) | $568.9K | 272,204 | 0.1% | 3 |
| EVOLUS INC | [EOLS](https://holderbook.com/stocks/EOLS/) | $541.7K | 78,057 | 0.1% | 3 |
| UNICYCIVE THERAPEUTICS INC | [UNCY](https://holderbook.com/stocks/UNCY/) | $521.1K | 103,400 | 0.1% | 2 |
| COMPASS THERAPEUTICS INC | [CMPX](https://holderbook.com/stocks/CMPX/) | $510.4K | 233,066 | 0.1% | 3 |
| BIOCRYST PHARMACEUTICALS INC | [BCRX](https://holderbook.com/stocks/BCRX/) | $510.2K | 51,024 | 0.1% | 2 |
| BRIGHT MINDS BIOSCIENCES INC | [DRUG](https://holderbook.com/stocks/DRUG/) | $448.9K | 6,395 | 0.1% | 2 |
| PROTHENA CORP PLC | [PRTA](https://holderbook.com/stocks/PRTA/) | $423.9K | 43,300 | 0.1% | 3 |
| MONTE ROSA THERAPEUTICS INC | [GLUE](https://holderbook.com/stocks/GLUE/) | $406.6K | 16,800 | 0.1% | 3 |
| OLEMA PHARMACEUTICALS INC | [OLMA](https://holderbook.com/stocks/OLMA/) | $393.8K | 31,476 | 0.1% | 1 |
| MILESTONE PHARMACEUTICALS IN | [MIST](https://holderbook.com/stocks/MIST/) | $362.1K | 270,233 | 0.1% | 2 |
| ENTERA BIO LTD | [ENTX](https://holderbook.com/stocks/ENTX/) | $338.7K | 191,354 | 0.1% | 3 |
| CUE BIOPHARMA INC | [CUE](https://holderbook.com/stocks/CUE/) | $337.8K | 10,702 | 0.1% | 1 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $331.2K | 6,000 | 0.1% | 1 |
| BEAM THERAPEUTICS INC | [BEAM](https://holderbook.com/stocks/BEAM/) | $302.2K | 8,804 | 0.0% | 3 |
| ASTRAZENECA PLC | [AZN](https://holderbook.com/stocks/AZN/) | $265.5K | 1,400 | 0.0% | 1 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $261.1K | 14,540 | 0.0% | 3 |
| STOKE THERAPEUTICS INC | [STOK](https://holderbook.com/stocks/STOK/) | $255.4K | 7,745 | 0.0% | 1 |
| VIKING THERAPEUTICS INC | [VKTX](https://holderbook.com/stocks/VKTX/) | $251.9K | 7,404 | 0.0% | 1 |
| LIPOCINE INC NEW | [LPCN](https://holderbook.com/stocks/LPCN/) | $201.8K | 78,842 | 0.0% | 2 |
| CORBUS PHARMACEUTICALS HLDGS | [CRBP](https://holderbook.com/stocks/CRBP/) | $201.0K | 21,432 | 0.0% | 3 |
| PROMIS NEUROSCIENCES INC | [PMN](https://holderbook.com/stocks/PMN/) | $139.5K | 10,600 | 0.0% | 2 |
| WAVE LIFE SCIENCES LTD | [WVE](https://holderbook.com/stocks/WVE/) | $99.8K | 19,048 | 0.0% | 1 |
| PMV PHARMACEUTICALS INC | [PMVP](https://holderbook.com/stocks/PMVP/) | $71.8K | 53,569 | 0.0% | 3 |
| FULCRUM THERAPEUTICS INC | [FULC](https://holderbook.com/stocks/FULC/) | $66.2K | 18,089 | 0.0% | 2 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $15.3K | 338 | 0.0% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q1 2026 | +32.6% | -4.6% | +37.3% | 99% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $605.9M | 96 |
| Q1 2026 | $315.1M | 114 |
| Q4 2025 | $147.8M | 85 |